95 related articles for article (PubMed ID: 27876270)
21. Biochemical Characterization of a New 10% IVIG Preparation [IgG Next Generation (BT595)/Yimmugo
Duellberg C; Hannappel A; Kistner S; Maneg O
Drugs R D; 2023 Sep; 23(3):245-255. PubMed ID: 37466834
[TBL] [Abstract][Full Text] [Related]
22. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products.
Romberg V; Hoefferer L; El Menyawi I
Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887
[TBL] [Abstract][Full Text] [Related]
23. Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice.
Xu Y; Liang Y; Parunov L; Despres D; Eckhaus M; Scott D; Ovanesov M; Struble EB
Thromb J; 2020 Nov; 18(1):32. PubMed ID: 33292285
[TBL] [Abstract][Full Text] [Related]
24. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies.
Vassilev TL; Bineva IL; Dietrich G; Kaveri SV; Kazatchkine MD
J Autoimmun; 1995 Jun; 8(3):405-13. PubMed ID: 7576001
[TBL] [Abstract][Full Text] [Related]
25. Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG.
Wu YW; Champagne J; Toueille M; Gantier R; Burnouf T
Transfusion; 2014 Jan; 54(1):169-78. PubMed ID: 23701287
[TBL] [Abstract][Full Text] [Related]
26. Influence of blood lipids on global coagulation test results.
Kim JA; Kim JE; Song SH; Kim HK
Ann Lab Med; 2015 Jan; 35(1):15-21. PubMed ID: 25553275
[TBL] [Abstract][Full Text] [Related]
27. A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance.
Parkkinen J; Rahola A; von Bonsdorff L; Tölö H; Törmä E
Vox Sang; 2006 Feb; 90(2):97-104. PubMed ID: 16430667
[TBL] [Abstract][Full Text] [Related]
28. Hypoperfusion in severely injured trauma patients is associated with reduced coagulation factor activity.
Jansen JO; Scarpelini S; Pinto R; Tien HC; Callum J; Rizoli SB
J Trauma; 2011 Nov; 71(5 Suppl 1):S435-40. PubMed ID: 22072000
[TBL] [Abstract][Full Text] [Related]
29. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products.
Hoefferer L; Glauser I; Gaida A; Willimann K; Marques Antunes A; Siani B; Wymann S; Widmer E; El Menyawi I; Bolli R; Spycher M; Imboden M
Transfusion; 2015 Jul; 55 Suppl 2():S117-21. PubMed ID: 26174889
[TBL] [Abstract][Full Text] [Related]
30. Functional integrity of intravenous immunoglobulin following irradiation with a virucidal dose of gamma radiation.
Tran H; Marlowe K; McKenney K; Petrosian G; Griko Y; Burgess WH; Drohan WN; Imboden MA; Kempf C; Boschetti N; Mann DM
Biologicals; 2004 Jun; 32(2):94-104. PubMed ID: 15454188
[TBL] [Abstract][Full Text] [Related]
31. Varicella-specific immunoglobulin G titers in commercial intravenous immunoglobulin preparations.
Maranich AM; Rajnik M
Pediatrics; 2009 Sep; 124(3):e484-8. PubMed ID: 19706589
[TBL] [Abstract][Full Text] [Related]
32. IgG subclasses distribution in immunoglobulin preparations for intravenous use.
Bozadjiev LG; Bineva IL; Vassilev TL
Arch Immunol Ther Exp (Warsz); 1992; 40(1):79-81. PubMed ID: 1485832
[TBL] [Abstract][Full Text] [Related]
33. Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis.
Raffa S; Reverter JC; Seijo S; Tassies D; Abraldes JG; Bosch J; García-Pagán JC
Clin Gastroenterol Hepatol; 2012 Jan; 10(1):72-8. PubMed ID: 21946303
[TBL] [Abstract][Full Text] [Related]
34. Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin.
Salvatore A; Esin S; Batoni G; Ascione E; Farina C; Nardini C
Transfusion; 2015 Jul; 55 Suppl 2():S110-6. PubMed ID: 26174888
[TBL] [Abstract][Full Text] [Related]
35. Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity.
Mina A; Favaloro EJ; Koutts J
Blood Coagul Fibrinolysis; 2012 Apr; 23(3):203-7. PubMed ID: 22322136
[TBL] [Abstract][Full Text] [Related]
36. Optimization of the thrombin generation test components to measure potency of factor VIII concentrates.
Jha NK; Shestopal SA; Gourley MJ; Woodle SA; Liang Y; Sarafanov AG; Weinstein M; Ovanesov MV
Haemophilia; 2016 Sep; 22(5):780-9. PubMed ID: 27038076
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G.
Fokkink WJ; Falck D; Santbergen TC; Huizinga R; Wuhrer M; Jacobs BC
PLoS One; 2015; 10(10):e0139828. PubMed ID: 26457892
[TBL] [Abstract][Full Text] [Related]
38. Factor XIa induced activation of the intrinsic cascade in vivo.
ten Cate H; Biemond BJ; Levi M; Wuillemin WA; Bauer KA; Barzegar S; Buller HR; Hack CE; ten Cate JW; Rosenberg RD
Thromb Haemost; 1996 Mar; 75(3):445-9. PubMed ID: 8701405
[TBL] [Abstract][Full Text] [Related]
39. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
[TBL] [Abstract][Full Text] [Related]
40. [Contamination of IgG preparation for intravenous use with IgA. I. Development of ELISA tests for determination of low concentrations of IgAc, IgA1, IgA2, IgG and IgM].
Dovezenski N; Velicković Z; Tosić Lj; Nikolić G; Popović O; Romić M; Djokić M; Mijusković Z
Srp Arh Celok Lek; 1994; 122 Suppl 1():49-50. PubMed ID: 18173186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
